-
1
-
-
33645526144
-
Cancer statistics, 2006
-
Jemal A., Spiegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
-
(2006)
CA Cancer J Clin
, vol.56
, pp. 106-130
-
-
Jemal, A.1
Spiegel, R.2
Ward, E.3
-
2
-
-
0345184913
-
Opportunities and challenges in the development of kinase inhibitor therapy for cancer
-
Sawyers C.L. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 17 (2003) 2998-3010
-
(2003)
Genes Dev
, vol.17
, pp. 2998-3010
-
-
Sawyers, C.L.1
-
3
-
-
1542398693
-
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
-
Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
-
(2004)
J Clin Oncol
, vol.22
, pp. 909-918
-
-
Atkins, M.B.1
Hidalgo, M.2
Stadler, W.M.3
-
4
-
-
0036632368
-
The phosphatidylinositol 3-kinase AKT pathway in human cancer
-
Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 489-501
-
-
Vivanco, I.1
Sawyers, C.L.2
-
5
-
-
0031833563
-
Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling
-
Abraham R.T. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 10 (1998) 330-336
-
(1998)
Curr Opin Immunol
, vol.10
, pp. 330-336
-
-
Abraham, R.T.1
-
6
-
-
0031755688
-
Studies on the mechanism of resistance to rapamycin in human cancer cells
-
Hosoi H., Dilling M.B., Liu L.N., et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 54 (1998) 815-824
-
(1998)
Mol Pharmacol
, vol.54
, pp. 815-824
-
-
Hosoi, H.1
Dilling, M.B.2
Liu, L.N.3
-
7
-
-
0033557578
-
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells
-
Hosoi H., Dilling M.B., Shikata T., et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59 (1999) 886-894
-
(1999)
Cancer Res
, vol.59
, pp. 886-894
-
-
Hosoi, H.1
Dilling, M.B.2
Shikata, T.3
-
8
-
-
0038141979
-
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins
-
Zhang Y., Gao X., Saucedo L.J., et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5 (2003) 578-581
-
(2003)
Nat Cell Biol
, vol.5
, pp. 578-581
-
-
Zhang, Y.1
Gao, X.2
Saucedo, L.J.3
-
9
-
-
0036713778
-
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
-
Inoki K., Li Y., Zhu T., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 (2002) 648-657
-
(2002)
Nat Cell Biol
, vol.4
, pp. 648-657
-
-
Inoki, K.1
Li, Y.2
Zhu, T.3
-
10
-
-
30644468118
-
mTOR and cancer: Reason for dancing at the crossroads?
-
Thomas G.V. mTOR and cancer: Reason for dancing at the crossroads?. Curr Opin Genet Dev 16 (2006) 78-84
-
(2006)
Curr Opin Genet Dev
, vol.16
, pp. 78-84
-
-
Thomas, G.V.1
-
11
-
-
2342559981
-
The TOR pathway: A target for cancer therapy
-
Bjornsti M.A., and Houghton P.J. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 4 (2004) 335-348
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 335-348
-
-
Bjornsti, M.A.1
Houghton, P.J.2
-
12
-
-
0344063370
-
Will mTOR inhibitors make it as cancer drugs?
-
Sawyers C.L. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell 4 (2003) 343-348
-
(2003)
Cancer Cell
, vol.4
, pp. 343-348
-
-
Sawyers, C.L.1
-
13
-
-
1642586272
-
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
-
Wendel H.G., De Stanchina E., Fridman J.S., et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
-
(2004)
Nature
, vol.428
, pp. 332-337
-
-
Wendel, H.G.1
De Stanchina, E.2
Fridman, J.S.3
-
14
-
-
0013840905
-
Tumour anoxia and the response to radiation
-
Thomlinson R. Tumour anoxia and the response to radiation. Sci Basis Med Annu Rev (1965) 74-90
-
(1965)
Sci Basis Med Annu Rev
, pp. 74-90
-
-
Thomlinson, R.1
-
15
-
-
84960987950
-
The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
-
Gray L., Conger A., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26 (1953) 638-648
-
(1953)
Br J Radiol
, vol.26
, pp. 638-648
-
-
Gray, L.1
Conger, A.2
Ebert, M.3
-
16
-
-
0034321578
-
Blood supply, oxygenation status and metabolic micromilieu of breast cancers: Characterization and therapeutic relevance
-
Vaupel P., and Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: Characterization and therapeutic relevance. Int J Oncol 17 (2000) 869-879
-
(2000)
Int J Oncol
, vol.17
, pp. 869-879
-
-
Vaupel, P.1
Hockel, M.2
-
17
-
-
0036359548
-
Hypoxia-A key regulatory factor in tumour growth
-
Harris A.L. Hypoxia-A key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 38-47
-
-
Harris, A.L.1
-
18
-
-
0025951716
-
Serial immunoreactive erythropoietin levels in autologous blood donors
-
Lorentz A., Jendrissek A., Eckardt K.U., et al. Serial immunoreactive erythropoietin levels in autologous blood donors. Transfusion 31 (1991) 650-654
-
(1991)
Transfusion
, vol.31
, pp. 650-654
-
-
Lorentz, A.1
Jendrissek, A.2
Eckardt, K.U.3
-
19
-
-
0036216692
-
HIF-1 and tumor progression: Pathophysiology and therapeutics
-
Semenza G.L. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med 8 (2002) S62-S67
-
(2002)
Trends Mol Med
, vol.8
-
-
Semenza, G.L.1
-
20
-
-
0035012605
-
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
-
Laughner E., Taghavi P., Chiles K., et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21 (2001) 3995-4004
-
(2001)
Mol Cell Biol
, vol.21
, pp. 3995-4004
-
-
Laughner, E.1
Taghavi, P.2
Chiles, K.3
-
21
-
-
0035503362
-
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer
-
Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61 (2001) 7992-7998
-
(2001)
Cancer Res
, vol.61
, pp. 7992-7998
-
-
Giatromanolaki, A.1
Koukourakis, M.I.2
Sivridis, E.3
-
22
-
-
0034654174
-
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
-
Zhong H., Chiles K., Feldser D., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
-
(2000)
Cancer Res
, vol.60
, pp. 1541-1545
-
-
Zhong, H.1
Chiles, K.2
Feldser, D.3
-
23
-
-
0033571682
-
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases
-
Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 (1999) 5830-5835
-
(1999)
Cancer Res
, vol.59
, pp. 5830-5835
-
-
Zhong, H.1
De Marzo, A.M.2
Laughner, E.3
-
24
-
-
0034654174
-
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
-
Zhong H., Chiles K., Feldser D., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
-
(2000)
Cancer Res
, vol.60
, pp. 1541-1545
-
-
Zhong, H.1
Chiles, K.2
Feldser, D.3
-
25
-
-
0034050050
-
Loss of PTEN facilitates HIF-1-mediated gene expression
-
Zundel W., Schindler C., Haas-Kogan D., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14 (2000) 391-396
-
(2000)
Genes Dev
, vol.14
, pp. 391-396
-
-
Zundel, W.1
Schindler, C.2
Haas-Kogan, D.3
-
26
-
-
0034925041
-
Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1
-
Jiang B.H., Jiang G., Zheng J.Z., et al. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12 (2001) 363-369
-
(2001)
Cell Growth Differ
, vol.12
, pp. 363-369
-
-
Jiang, B.H.1
Jiang, G.2
Zheng, J.Z.3
-
27
-
-
0142166332
-
Targeting HIF-1 for cancer therapy
-
Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 721-732
-
-
Semenza, G.L.1
-
28
-
-
0041920901
-
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
-
Brugarolas J.B., Vazquez F., Reddy A., et al. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 (2003) 147-158
-
(2003)
Cancer Cell
, vol.4
, pp. 147-158
-
-
Brugarolas, J.B.1
Vazquez, F.2
Reddy, A.3
-
29
-
-
0036718539
-
Molecular basis of the VHL hereditary cancer syndrome
-
Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2 (2002) 673-682
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 673-682
-
-
Kaelin, W.G.1
-
30
-
-
0027238288
-
Molecular genetic studies of sporadic and familial renal cell carcinoma
-
Gnarra J.R., Glenn G.M., Latif F., et al. Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am 20 (1993) 207-216
-
(1993)
Urol Clin North Am
, vol.20
, pp. 207-216
-
-
Gnarra, J.R.1
Glenn, G.M.2
Latif, F.3
-
31
-
-
0027954044
-
Mutations of the VHL tumour suppressor gene in renal carcinoma
-
Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7 (1994) 85-90
-
(1994)
Nat Genet
, vol.7
, pp. 85-90
-
-
Gnarra, J.R.1
Tory, K.2
Weng, Y.3
-
32
-
-
0028072991
-
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
-
Herman J.G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91 (1994) 9700-9704
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, pp. 9700-9704
-
-
Herman, J.G.1
Latif, F.2
Weng, Y.3
-
33
-
-
0033587146
-
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
-
Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
-
(1999)
Nature
, vol.399
, pp. 271-275
-
-
Maxwell, P.H.1
Wiesener, M.S.2
Chang, G.W.3
-
34
-
-
0033776536
-
Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein
-
Ohh M., Park C.W., Ivan M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2 (2000) 423-427
-
(2000)
Nat Cell Biol
, vol.2
, pp. 423-427
-
-
Ohh, M.1
Park, C.W.2
Ivan, M.3
-
35
-
-
0036527785
-
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma
-
Maranchie J.K., Vasselli J.R., Riss J., et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (2002) 247-255
-
(2002)
Cancer Cell
, vol.1
, pp. 247-255
-
-
Maranchie, J.K.1
Vasselli, J.R.2
Riss, J.3
-
36
-
-
0036528246
-
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
-
Kondo K., Klco J., Nakamura E., et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
-
(2002)
Cancer Cell
, vol.1
, pp. 237-246
-
-
Kondo, K.1
Klco, J.2
Nakamura, E.3
-
37
-
-
0035312747
-
Regulation of translation initiation by FRAP/mTOR
-
Gingras A.C., Raught B., and Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 15 (2001) 807-826
-
(2001)
Genes Dev
, vol.15
, pp. 807-826
-
-
Gingras, A.C.1
Raught, B.2
Sonenberg, N.3
-
38
-
-
0035233058
-
Control of translation by the target of rapamycin proteins
-
Gingras A.C., Raught B., and Sonenberg N. Control of translation by the target of rapamycin proteins. Prog Mol Subcell Biol 27 (2001) 143-174
-
(2001)
Prog Mol Subcell Biol
, vol.27
, pp. 143-174
-
-
Gingras, A.C.1
Raught, B.2
Sonenberg, N.3
-
39
-
-
0000183432
-
CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study
-
(abstr)
-
Hidalgo M., Rowinsky E., Erlichman C., et al. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study. Proc Am Soc Clin Oncol 19 (2000) 726A (abstr)
-
(2000)
Proc Am Soc Clin Oncol
, vol.19
-
-
Hidalgo, M.1
Rowinsky, E.2
Erlichman, C.3
-
41
-
-
9144233506
-
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
-
Bouley A., Zumstein S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64 (2004) 252-261
-
(2004)
Cancer Res
, vol.64
, pp. 252-261
-
-
Bouley, A.1
Zumstein, S.2
Stephan, C.3
-
42
-
-
29244459713
-
Mammalian target of rapamycin as a therapeutic target in leukemia
-
Giles F.J., and Albitar M. Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 5 (2005) 653-661
-
(2005)
Curr Mol Med
, vol.5
, pp. 653-661
-
-
Giles, F.J.1
Albitar, M.2
-
43
-
-
27644447574
-
The mammalian target of the rapamycin (mTOR) kinase pathway: Its role in tumourigenesis and targeted antitumour therapy
-
Jonas A., Robak T., and Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: Its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 10 (2005) 479-498
-
(2005)
Cell Mol Biol Lett
, vol.10
, pp. 479-498
-
-
Jonas, A.1
Robak, T.2
Smolewski, P.3
-
44
-
-
11344271046
-
Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer
-
Boni J.P., Leister C., Bender G., et al. Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 77 (2005) 76-89
-
(2005)
Clin Pharmacol Ther
, vol.77
, pp. 76-89
-
-
Boni, J.P.1
Leister, C.2
Bender, G.3
-
45
-
-
0003166055
-
CCI-779, a rapamycin analogue with antitumor activity: A phase I study utilizing a weekly schedule
-
(abstr)
-
Raymond E., Alexandre J., Depenbrock H., et al. CCI-779, a rapamycin analogue with antitumor activity: A phase I study utilizing a weekly schedule. Proc Am Soc Clin Oncol 19 (2000) 187a (abstr)
-
(2000)
Proc Am Soc Clin Oncol
, vol.19
-
-
Raymond, E.1
Alexandre, J.2
Depenbrock, H.3
-
46
-
-
8344281974
-
Targeting the molecular target of rapamycin (mTOR)
-
Rowinsky E.K. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 16 (2004) 564-575
-
(2004)
Curr Opin Oncol
, vol.16
, pp. 564-575
-
-
Rowinsky, E.K.1
-
47
-
-
33749623087
-
-
ASCO/AACR/EORTC International Conference on Medical Therapeutics, Philadelphia, PA
-
Cho D., Signoretti S., Regan M., et al. Low expression of surrogates for mTOR pathway activation predict for resistance to CCI-779 in patients with advanced renal cell carcinoma (RCC) (2005), ASCO/AACR/EORTC International Conference on Medical Therapeutics, Philadelphia, PA
-
(2005)
Low expression of surrogates for mTOR pathway activation predict for resistance to CCI-779 in patients with advanced renal cell carcinoma (RCC)
-
-
Cho, D.1
Signoretti, S.2
Regan, M.3
-
48
-
-
17944377486
-
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
-
Neshat M.S., Mellinghoff I.K., Tran C., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98 (2001) 10314-10319
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, pp. 10314-10319
-
-
Neshat, M.S.1
Mellinghoff, I.K.2
Tran, C.3
-
49
-
-
0038615946
-
Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo
-
Choe G., Horvath S., Cloughesy T.F., et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63 (2003) 2742-2746
-
(2003)
Cancer Res
, vol.63
, pp. 2742-2746
-
-
Choe, G.1
Horvath, S.2
Cloughesy, T.F.3
-
50
-
-
19944427667
-
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer
-
Thomas G.V., Horvath S., Smith B.L., et al. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 10 (2004) 8351-8356
-
(2004)
Clin Cancer Res
, vol.10
, pp. 8351-8356
-
-
Thomas, G.V.1
Horvath, S.2
Smith, B.L.3
-
51
-
-
24144481478
-
Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway
-
(abstr)
-
Pantuck A.J., Seligson D., Wu H., et al. Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J Urol 173 (2005) 96a (abstr)
-
(2005)
J Urol
, vol.173
-
-
Pantuck, A.J.1
Seligson, D.2
Wu, H.3
-
52
-
-
30044432434
-
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
-
Thomas G.V., Tran C., Mellinghof I., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006) 122
-
(2006)
Nat Med
, vol.12
, pp. 122
-
-
Thomas, G.V.1
Tran, C.2
Mellinghof, I.3
|